The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 19, 2021

Filed:

Mar. 23, 2017
Applicant:

Gensun Biopharma Inc., Newbury Park, CA (US);

Inventors:

Jackie Sheng, Thousand Oaks, CA (US);

Bo Liu, Thousand Oaks, CA (US);

Haiqun Jia, Thousand Oaks, CA (US);

Assignee:

GENSUN BIOPHARMA INC., Newbury Park, CA;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/22 (2006.01); C07K 16/46 (2006.01); C07K 16/28 (2006.01); A61K 38/18 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/22 (2013.01); A61K 38/1891 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2863 (2013.01); C07K 16/468 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/60 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/66 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2318/20 (2013.01); C07K 2319/30 (2013.01);
Abstract

A trispecific inhibitor for treating cancer includes a first targeting domain having a binding specificity conferred by a VEGF binding antagonist; a second targeting domain having a binding specificity conferred by an immune checkpoint regulator binding antagonist; and a third targeting domain having a binding specificity conferred by a Tie2 tyrosine kinase receptor binding antagonist. The targeting domains may contain one or more antibody variable regions, peptide inhibitors, dominant negative proteins, small molecule drugs or combinations thereof.


Find Patent Forward Citations

Loading…